Discontinuation due to factors typically irrelevant in clinical trial settings (i.e., cost or insurance-related issues and medication shortages) could contribute to the substantial discrepancy between discontinuation rates in pivotal phase 3 trials and those reported in real-world studies. Regarding discontinuation due to side effects, Gasoyan says we do not currently know of patient-level predictors that would help identify who might experience side effects and why
The SeekPeptides toolkit For researchers serious about optimizing their GLP-1 protocols, SeekPeptides brings together the peptide calculator , reconstitution calculator , cost calculator , and comprehensive protocol guides in one platform
Avoid strenuous activities that target the area for the first few hours
WIREs Nanomed Nanobiotechnol
[BIG CTA GRAPHIC/BUTTON HERE] The Bottom Line Traveling while on a GLP-1 program takes a little planning
Wegovy has a safety advantage for people without gallbladders compared to some alternatives